Antibody-mediated blockade of CXCL16
To neutralize the activity of CXCL16 in severe CLP, rat anti-mouse CXCL16 neutralizing monoclonal antibody (R&D systems, monoclonal rat IgG2A Clone # 142417) was used. The neutralization ability of anti-CXCL16 monoclonal antibody has been confirmed by its capacity to neutralize CXCL16-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with mouse CXCR6. The Neutralization Dose (ND50) is typically 0.15-0.6 µg/mL in the presence of 7.5 ng/mL recombinant mouse CXCL16 chemokine domain (R&D systems, Catalog # 503-CX-025)). In mouse studies, 10 μg of anti-mouse CXCL16 neutralizing monoclonal antibody was injected i.p. in 50 μl of PBS 2 hours after CLP, and rat IgG2A control antibody was used as control.